Literature DB >> 3801087

Probucol prevents lipid storage in macrophages.

A Yamamoto, S Takaichi, H Hara, O Nishikawa, S Yokoyama, T Yamamura, T Yamaguchi.   

Abstract

Effects of probucol on lipid storage in macrophages in vitro in the presence of acetylated low density lipoprotein (acetyl-LDL) were observed using macrophage-like cells (UE-12) established from a human histiocytic lymphoma cell line (U-937). Under ordinary light microscopy as well as under electron microscopy we found that probucol added to the medium, either in ethanolic solution or bound to LDL, markedly prevented the development of macrophages into foam cells. Microscale enzymatic assay of cholesterol also showed that the intracellular accumulation of esterified cholesterol caused by acetyl-LDL was markedly decreased by the addition of probucol. The concentration of probucol added to the medium was almost comparable to the plasma concentration of the drug usually obtained in patients under treatment with probucol. The possibility that probucol interferes with the binding of acetyl-LDL to the receptors on the cell surface was suggested. The results of the present investigation coincide with the clinical findings that probucol causes a more marked regression of xanthomas than would be expected from the extent of lowering of LDL cholesterol.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3801087     DOI: 10.1016/0021-9150(86)90095-x

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  10 in total

1.  Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits.

Authors:  A Daugherty; B S Zweifel; G Schonfeld
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

2.  Macrophages enhance binding of beta-VLDL and cholesterol ester accumulation in cultured aortic smooth muscle cells.

Authors:  R E Rennick; J H Campbell; G R Campbell
Journal:  Heart Vessels       Date:  1994       Impact factor: 2.037

3.  Evidence for an additional intracellular site of action of probucol in the prevention of oxidative modification of low density lipoprotein. Use of a new water-soluble probucol derivative.

Authors:  S Parthasarathy
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

Review 4.  Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia.

Authors:  M M Buckley; K L Goa; A H Price; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

5.  Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit.

Authors:  T E Carew; D C Schwenke; D Steinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

6.  Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia.

Authors:  T Kita; Y Nagano; M Yokode; K Ishii; N Kume; A Ooshima; H Yoshida; C Kawai
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

7.  Probucol inhibits neointimal thickening and macrophage accumulation after balloon injury in the cholesterol-fed rabbit.

Authors:  G A Ferns; L Forster; A Stewart-Lee; M Konneh; J Nourooz-Zadeh; E E Anggård
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

8.  The effects of probucol on the progression of atherosclerosis in mature Watanabe heritable hyperlipidaemic rabbits.

Authors:  A Daugherty; B S Zweifel; G Schonfeld
Journal:  Br J Pharmacol       Date:  1991-05       Impact factor: 8.739

9.  High Density Lipoprotein-Based Therapeutics: Novel Mechanism of Probucol in Foam Cells.

Authors:  Anouar Hafiane; Annalisa Ronca; Robert S Kiss; Elda Favari
Journal:  Front Cardiovasc Med       Date:  2022-04-26

10.  Integrated Analysis of Two Probucol Trials for the Secondary Prevention of Atherosclerotic Cardiovascular Events: PROSPECTIVE and IMPACT.

Authors:  Hidenori Arai; Hideaki Bujo; Daisaku Masuda; Toshiyuki Ishibashi; Satoshi Nakagawa; Kenichiro Tanabe; Tatsuo Kagimura; Hyun-Jae Kang; Moo Hyun Kim; Jidong Sung; Sang-Hyun Kim; Cheol-Ho Kim; Jeong Euy Park; Junbo Ge; Byung-Hee Oh; Toru Kita; Yasushi Saito; Masanori Fukushima; Yuji Matsuzawa; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2021-04-18       Impact factor: 4.394

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.